Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

204.26
-3.5200-1.69%
Volume:180.35K
Turnover:37.28M
Market Cap:10.70B
PE:-54.20
High:210.85
Open:208.17
Low:203.47
Close:207.78
52wk High:260.19
52wk Low:114.91
Shares:52.38M
Float Shares:43.83M
Volume Ratio:0.41
T/O Rate:0.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7685
EPS(LYR):-3.6821
ROE:-245.10%
ROA:-16.31%
PB:128.44
PE(LYR):-55.47

Loading ...

Axsome Presents Alzheimer’s Agitation Caregiver Survey Results at Psych Congress 2026

Reuters
·
Yesterday

Axsome Therapeutics Price Target Maintained with a $258.00/Share by Piper Sandler

Dow Jones
·
Sep 19

Axsome's Auvelity Launch Shows Early Strength in Alzheimer's Agitation, RBC Says

MT Newswires Live
·
Sep 18

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), BioMarin Pharmaceutical (BMRN) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Sep 18

Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026

GlobeNewswire
·
Sep 17

Movement Alert|Axsome Therapeutics Rises 6.24% in Regular Trading, Auvelity Prescription Growth Fuels Market Confidence

Market Focus
·
Sep 12

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN)

TIPRANKS
·
Sep 10

Axsome COO Mark Jacobson Sells 10,000 Shares for $2.09 Million

Reuters
·
Sep 04

Axsome Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Sep 02

Axsome Therapeutics' Auvelity Could Drive Revenue Beats After Launch in Alzheimer's Agitation, RBC Says

MT Newswires Live
·
Sep 01

Axsome Therapeutics Price Target Maintained with a $290.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 31

Axsome pullback brings attractive entry point, says H.C. Wainwright

TIPRANKS
·
Aug 31

Axsome Therapeutics, - Doses First Patient in Summit Phase 3 Trial of Axs-05 for Smoking Cessation

THOMSON REUTERS
·
Aug 31

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

GlobeNewswire
·
Aug 31

The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Rising Revenue And Widening Net Losses

Simply Wall St.
·
Aug 24

Axsome Therapeutics (AXSM) Stock Still Trades Below Fair Value On Sales

Simply Wall St.
·
Aug 21

UBS Adjusts Price Target on Axsome Therapeutics to $280 From $259, Keeps Buy Rating

MT Newswires Live
·
Aug 12

Liquidia Q2 Revenue Jumps on Yutrepia Sales

Reuters
·
Aug 12

Axsome Therapeutics (AXSM) Receives a Buy from Mizuho Securities

TIPRANKS
·
Aug 12

Axsome's Auvelity Strength Expected to Drive H2 Revenue Growth, RBC Says

MT Newswires Live
·
Aug 11